Thursday, May 5, 2016

Prostate cancer drugs DOUBLE the risk of Alzheimer’s

… which sells even more drugs for Big Pharma
Submitted by IWB, on May 4th, 2016 


by: Daniel Barker



(NaturalNews) Prostate cancer patients who receive hormone therapy as part of their treatment are twice as likely to develop Alzheimer’s and face an increased risk of depression, a pair of recent studies has shown. 


A common treatment for prostate cancer involves the use of androgen-deprivation therapy (ADT) drugs, which reduce testosterone levels, which is required by prostate cancer cells so that they can grow and spread.

Two separate research projects focused on ADT drugs and discovered side effects other than those already associated with their use, such as weight gain, fatigue, reduced libido and sexual dysfunction.  Hormone therapy and depression risk

The most recent of the two studies (both published in the Journal of Clinical Oncology), found a link between ADT and an elevated risk of depression among the nearly 45,000 men tested who had received the treatment.

Patients with prostate cancer who received hormone therapy were 23 percent more likely to develop depression and 29 percent more likely to have inpatient psychiatric treatment than men who received alternative treatments, the study found. …

REad more http://investmentwatchblog.com/prostate-cancer-drugs-double-the-risk-of-alzheimers-which-sells-even-more-drugs-for-big-pharma/